Baricitinib
- Generic Name
- Baricitinib
- Brand Names
- Olumiant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N7O2S
- CAS Number
- 1187594-09-7
- Unique Ingredient Identifier
- ISP4442I3Y
- Background
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...
- Indication
In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...
- Associated Conditions
- Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT02759731
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Baricitinib (LY3009104) in Healthy Chinese Participants
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT02758613
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Beijing, China
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 314
- Registration Number
- NCT02708095
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 124
- Registration Number
- NCT02576938
- Locations
- 🇺🇸
Medical Dermatology Specialists, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Menter Dermatology Research Institute, Dallas, Texas, United States
A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT02340104
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY, Leeds, Yorkshire, United Kingdom
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 290
- Registration Number
- NCT02265705
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., ZhuZhou, China
A Study of Baricitinib in Healthy Japanese Participants
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT02263911
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Tokyo, Japan
A Study of Baricitinib and Ciclosporin in Healthy Participants
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01968057
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Baricitinib and Simvastatin in Healthy Participants
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT01960140
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.